Regan-Fendt, K.; Li, D.; Reyes, R.; Yu, L.; Wani, N.A.; Hu, P.; Jacob, S.T.; Ghoshal, K.; Payne, P.R.O.; Motiwala, T.
Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers 2020, 12, 2730.
https://doi.org/10.3390/cancers12102730
AMA Style
Regan-Fendt K, Li D, Reyes R, Yu L, Wani NA, Hu P, Jacob ST, Ghoshal K, Payne PRO, Motiwala T.
Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers. 2020; 12(10):2730.
https://doi.org/10.3390/cancers12102730
Chicago/Turabian Style
Regan-Fendt, Kelly, Ding Li, Ryan Reyes, Lianbo Yu, Nissar A. Wani, Peng Hu, Samson T. Jacob, Kalpana Ghoshal, Philip R.O. Payne, and Tasneem Motiwala.
2020. "Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma" Cancers 12, no. 10: 2730.
https://doi.org/10.3390/cancers12102730
APA Style
Regan-Fendt, K., Li, D., Reyes, R., Yu, L., Wani, N. A., Hu, P., Jacob, S. T., Ghoshal, K., Payne, P. R. O., & Motiwala, T.
(2020). Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers, 12(10), 2730.
https://doi.org/10.3390/cancers12102730